Clinical comparability of marketed formulations of botulinum toxin-Reference-Cited by-同舟云学术

Clinical comparability of marketed formulations of botulinum toxin

Published:2004 Issue:S8 Volume:19 Page:S129-S136
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Sampaio Cristina,Costa Jo�o,Ferreira Joaquim J.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference43 articles.

1. Botulinum toxin: from poison to pharmaceutical the history of a poison that became useful to mankind. 2002; 30: 94-100.

2. Botulinum Toxin as a Biological Weapon

3. Therapeutic botulinum type a toxin: Factors affecting potency

4. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) Note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance. CPMP/BWP/3207/00.

5. DOSE STANDARDISATION OF BOTULINUM TOXIN

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Insights into the Formulation and Delivery of Therapeutic and Cosmeceutical Agents for Aging Skin;Cosmetics;2023-03-25

2. Botulinum toxin – Know the product before injecting;Cosmoderma;2021-10-18

3. AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol;Advances in Therapy;2021-09-25

4. Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care;Frontiers in Neurology;2021-07-01

5. The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache: a systematic review and meta-analysis of randomized, placebo-controlled trials;Scandinavian Journal of Pain;2021-06-07